Page last updated: 2024-11-08
cantharidin and Itching
cantharidin has been researched along with Itching in 2 studies
Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.
cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy." | 9.41 | Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. ( Burnett, P; Davidson, M; Eichenfield, LF; Glover, D; Kwong, P; McBride, M; Olivadoti, M; Rieger, J; Siegfried, E; Willson, C, 2021) |
| " Safety outcomes included assessment of adverse events, including expected local skin reactions." | 6.94 | Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. ( Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020) |
| "Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy." | 5.41 | Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. ( Burnett, P; Davidson, M; Eichenfield, LF; Glover, D; Kwong, P; McBride, M; Olivadoti, M; Rieger, J; Siegfried, E; Willson, C, 2021) |
| " Safety outcomes included assessment of adverse events, including expected local skin reactions." | 2.94 | Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials. ( Brabec, B; Burnett, P; Davidson, M; Eichenfield, LF; Kwong, P; McBride, M; McFalda, W; Rieger, J; Siegfried, E; Willson, C, 2020) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Eichenfield, LF | 2 |
| McFalda, W | 1 |
| Brabec, B | 1 |
| Siegfried, E | 2 |
| Kwong, P | 2 |
| McBride, M | 2 |
| Rieger, J | 2 |
| Willson, C | 2 |
| Davidson, M | 2 |
| Burnett, P | 2 |
| Glover, D | 1 |
| Olivadoti, M | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum[NCT03377803] | Phase 3 | 262 participants (Actual) | Interventional | 2018-02-14 | Completed |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum[NCT03377790] | Phase 3 | 266 participants (Actual) | Interventional | 2018-03-21 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit
Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | change in wart count from baseline (Mean) |
|---|
| VP-102 | -17.1 |
| Placebo | -10.9 |
Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit
Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | percentage change from Baseline (Mean) |
|---|
| VP-102 | -83.3 |
| Placebo | -19.1 |
Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit
Percentage of subjects exhibiting a 75% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84(EOS)
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 122 |
| Placebo | 40 |
Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit
Percentage of subjects exhibiting a 90% or greater reduction of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 105 |
| Placebo | 31 |
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 21
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 8 |
| Placebo | 2 |
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 42
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 19 |
| Placebo | 4 |
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 63
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 42 |
| Placebo | 5 |
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). (NCT03377803)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 81 |
| Placebo | 15 |
Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject
Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. (NCT03377803)
Timeframe: Days 1, 21, 42, 63 and 84 (EOS).
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 10 |
| Placebo | 7 |
Change From Baseline of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age
"Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.~From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the~CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome)." (NCT03377803)
Timeframe: Day 1 (Baseline), 21, 42, 63 and Day 84 (EOS)
| Intervention | score on a scale (Mean) |
|---|
| Day 21 | Day 42 | Day 63 | Day 84 (EOS) |
|---|
| Placebo | -1.2 | -1.4 | -1.6 | -1.9 |
,| VP-102 | -1.0 | -1.5 | -2.0 | -2.1 |
Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | change in wart count (Mean) |
|---|
| VP-102 | -18.3 |
| Placebo | -5.9 |
Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.
"Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.~From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the~CDLQI, a score of 0-3 was assigned using the following scores per response:~3: Very much (or Prevented School, Question 7 only)~2: Quite a lot~1: Only a little~0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome)." (NCT03377790)
Timeframe: Baseline to Day 84 (EOS)
| Intervention | units on a scale (Mean) |
|---|
| VP-102 | -2.1 |
| Placebo | -2.7 |
Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit
Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | percentage of change in wart count (Mean) |
|---|
| VP-102 | -69.2 |
| Placebo | 20.0 |
Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
Percentage of subjects that exhibited a 75% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 119 |
| Placebo | 36 |
Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit.
Percentage of subjects that exhibited a 90% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. (NCT03377790)
Timeframe: Day 1 (Baseline) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 99 |
| Placebo | 28 |
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 42
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 33 |
| Placebo | 10 |
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 63
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 51 |
| Placebo | 18 |
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS)
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 84 (EOS)
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 74 |
| Placebo | 19 |
Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit
Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. (NCT03377790)
Timeframe: Day 1 (Baseline and new) compared to Day 21
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 18 |
| Placebo | 4 |
Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject.
Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. To be eligible for assessment, subjects had to have at least one household member free of lesions at baseline and have at least 1 post baseline assessment of spread of molluscum lesions. (NCT03377790)
Timeframe: Days 1, 21, 42, 63 and 84 (EOS).
| Intervention | Participants (Count of Participants) |
|---|
| VP-102 | 9 |
| Placebo | 13 |
Trials
2 trials available for cantharidin and Itching
| Article | Year |
|---|
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.JAMA dermatology, 2020, 12-01, Volume: 156, Issue:12
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr | 2020 |
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.JAMA dermatology, 2020, 12-01, Volume: 156, Issue:12
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr | 2020 |
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.JAMA dermatology, 2020, 12-01, Volume: 156, Issue:12
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr | 2020 |
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.JAMA dermatology, 2020, 12-01, Volume: 156, Issue:12
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Dr | 2020 |
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.American journal of clinical dermatology, 2021, Volume: 22, Issue:2
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq | 2021 |
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.American journal of clinical dermatology, 2021, Volume: 22, Issue:2
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq | 2021 |
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.American journal of clinical dermatology, 2021, Volume: 22, Issue:2
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq | 2021 |
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.American journal of clinical dermatology, 2021, Volume: 22, Issue:2
Topics: Administration, Cutaneous; Adolescent; Cantharidin; Child; Child, Preschool; Double-Blind Method; Eq | 2021 |